Axa’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-79,392
| Closed | -$5.07M | – | 1175 |
|
|
2025
Q1 | $5.07M | Buy |
79,392
+20,540
| +35% | +$2.16M | 0.02% | 535 |
|
|
2024
Q4 | $7.16M | Sell |
58,852
-93
| -0.2% | -$11.4K | 0.02% | 452 |
|
|
2024
Q3 | $7.36M | Buy |
58,945
+18
| +0% | +$2.49K | 0.02% | 456 |
|
|
2024
Q2 | $9.31M | Buy |
58,927
+33
| +0.1% | +$4.24K | 0.03% | 401 |
|
|
2024
Q1 | $7.62M | Buy |
58,894
+15
| +0% | +$1.84K | 0.02% | 461 |
|
|
2023
Q4 | $5.68M | Sell |
58,879
-1,425
| -2% | -$137K | 0.02% | 524 |
|
|
2023
Q3 | $7.31M | Sell |
60,304
-214
| -0.4% | -$24.2K | 0.03% | 456 |
|
|
2023
Q2 | $6.93M | Buy |
60,518
+833
| +1% | +$107K | 0.02% | 483 |
|
|
2023
Q1 | $8.23M | Sell |
59,685
-37,889
| -39% | -$4.91M | 0.03% | 449 |
|
|
2022
Q4 | $12.6M | Sell |
97,574
-531
| -0.5% | -$61.5K | 0.05% | 390 |
|
|
2022
Q3 | $10.8M | Buy |
98,105
+413
| +0.4% | +$41.6K | 0.04% | 416 |
|
|
2022
Q2 | $7.32M | Sell |
97,692
-1,904
| -2% | -$140K | 0.03% | 492 |
|
|
2022
Q1 | $7.78M | Sell |
99,596
-1
| -0% | -$77 | 0.02% | 536 |
|
|
2021
Q4 | $8.97M | Buy |
99,597
+1,190
| +1% | +$102K | 0.02% | 525 |
|
|
2021
Q3 | $9.1M | Buy |
98,407
+3,617
| +4% | +$279K | 0.03% | 522 |
|
|
2021
Q2 | $7.37M | Sell |
94,790
-7,199
| -7% | -$546K | 0.02% | 599 |
|
|
2021
Q1 | $7.6M | Buy |
101,989
+30,107
| +42% | +$2.78M | 0.02% | 584 |
|
|
2020
Q4 | $12.3M | Buy |
71,882
+2,897
| +4% | +$429K | 0.04% | 453 |
|
|
2020
Q3 | $9.69M | Sell |
68,985
-6,005
| -8% | -$913K | 0.04% | 469 |
|
|
2020
Q2 | $12M | Buy |
74,990
+8,319
| +12% | +$1.13M | 0.05% | 385 |
|
|
2020
Q1 | $6.52M | Buy |
66,671
+3,715
| +6% | +$425K | 0.03% | 456 |
|
|
2019
Q4 | $8.12M | Buy |
62,956
+1,470
| +2% | +$148K | 0.03% | 496 |
|
|
2019
Q3 | $4.63M | Sell |
61,486
-99
| -0.2% | -$11.7K | 0.02% | 676 |
|
|
2019
Q2 | $9.36M | Sell |
61,585
-20,776
| -25% | -$2.52M | 0.04% | 491 |
|
|
2019
Q1 | $9.82M | Sell |
82,361
-4,600
| -5% | -$591K | 0.04% | 462 |
|
|
2018
Q4 | $9.49M | Sell |
86,961
-100
| -0.1% | -$12.5K | 0.04% | 430 |
|
|
2018
Q3 | $14.1M | Sell |
87,061
-46
| -0.1% | -$6.29K | 0.05% | 385 |
|
|
2018
Q2 | $11.5M | Buy |
87,107
+27,514
| +46% | +$2.59M | 0.04% | 409 |
|
|
2018
Q1 | $4.42M | Buy |
+59,593
| New | +$3.97M | 0.02% | 686 |
|
|
2015
Q1 | – | Sell |
-84,400
| Closed | -$1.22M | – | 1486 |
|
|
2014
Q4 | $1.22M | Buy |
+84,400
| New | +$1.43M | ﹤0.01% | 921 |
|
Other funds holding SRPT
EAM
Axa's SRPT Position: Q2 2025 in Review
Axa sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 79,392 shares — an estimated $5.07M sold.
Axa first reported a position in SRPT in Q4 2014 and held it in 30 quarters. The position peaked at $14.1M in Q3 2018. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.
- Axa reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
- Axa sold 79,392 Sarepta Therapeutics shares in Q2 2025, an estimated $5.07M.
- Axa first reported a position in Sarepta Therapeutics in Q4 2014 and held it in 30 quarters.
- Axa's Sarepta Therapeutics position peaked at $14.1M in Q3 2018.
- 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.
Based on Axa's 13F filing for Q2 2025, filed 14 Aug 2025.